Caroline Day is visiting fellow, School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK.
Glucose-lowering drugs and cardiovascular risk: how recent outcome trials have informed practiceSubscription
Although large clinical trials with glucose-lowering drugs have consistently shown beneficial reductions in microvascular complications, their effects on macrovascular complications have been controversial. Interpreting these trials is complicated by substantial differences in their design, the populations studied and data analysis. This article examines how the trials have evolved and how they impact the use of glucose-lowering agents in the routine care of patients with type 2 diabete